Mitochondrial Stress as a Central Biological Hub for Spaceflight Impact
During the Targeting Mitochondria 2023 congress, Dr. Afshin Beheshti, Blue Marble Space Institute of Science, USA will give a presentation entitled "Mitochondrial Stress as a Central Biological Hub for Spaceflight Impact".
Join Targeting Mitochondria 2023 to learn more about Dr. Beheshti's talk.
Targeting Mitochondria 2023 Congress
October 11-13, 2023 - Berlin, Germany
Protein Transport across Mitochondrial Membranes
Dr. Peter Rehling, from University Medical Center Göttingen, Germany will join the Targeting Mitochondria 2023 congress and present his research on "Protein Transport across Mitochondrial Membranes".
In his talk, Dr. Rehling will share his latest research on the molecular mechanisms of protein import into mitochondria, focusing on recent advances in understanding the role of protein chaperones and translocases.
Join Targeting Mitochondria 2023 to learn more about Prof. Rehling's interesting talk.
Targeting Mitochondria 2023 Congress
October 11-13, 2023 - Berlin, Germany
The role of Mitochondria in Liver Regeneration
Prof. Jiri Neuzil from Griffith University, Australia will join the Targeting Mitochondria 2023 congress which will be held on October 11-13, 2023 in Berlin, Germany, and will present a talk entitled "The role of Mitochondria in Liver Regeneration".
Prof. Neuzil focuses on the role of mitochondria in cancer. Major projects of his laboratory are mitochondria as a target for cancer therapy; horizontal transfer of mitochondria; the role of respiratory complexes in the biology and function of mitochondria; role of metabolic switch in malignant transformation and tissue regeneration. He developed a novel anti-cancer drug, mitochondrially targeted tamoxifen (MitoTam), an analogue of tamoxifen tagged with a delocalized cation (triphenylphosphonium) that preferentially targets the inner mitochondrial membrane of cancer cells, interfering with mitochondrial respiratory complex I. MitoTam has recently underwent Phase I/Ib clinical trial with efficacy against renal cell carcinoma.
Prof. Neuzil obtained his Ph.D. from the Institute of Microbiology in Prague, then he was a post-doctoral fellow at the Heart Research Institute in Sydney, Australia. After 3 years at the University of Munich as a Junior Group Leader and one year as a visiting researcher at the University of Linkoping (Sweden), he got the position of Senior lecturer in 2002 (later on Associate Professor and Professor) at Griffith University in Southport, Qld, Australia. Since 2006, he is a Group Leader at the Institute of Biotechnology, Czech Academy of Sciences in Prague. He has published over 245 scientific papers and his HI is 62.
Join Targeting Mitochondria 2023 to learn more about Prof. Neuzil's talk.
Targeting Mitochondria 2023 Congress
October 11-13, 2023 - Berlin, Germany
Restoration of Mitochondrial Homeostasis provides Glaucoma Neuroprotection
Prof
. Arupratan Das from Indiana University School of Medicine, USA will join the Targeting Mitochondria 2023 congress and present his study on "Restoration of Mitochondrial Homeostasis provides Glaucoma Neuroprotection".
Neurons are highly energy-demanding due to their constant need for neurotransmission and synaptic activity. Mitochondria are the primary source for cellular energy currency adenosine triphosphate (ATP), and dysfunctional mitochondria present a key pathological condition for the central nervous system (CNS) disorders such as glaucoma, amyotrophic lateral sclerosis (ALS) and Parkinson’s disease. Retinal ganglion cells (RGCs) of the optic nerve are particularly vulnerable to mitochondrial dysfunctions as they need steady supply of ATP for varying frequency of action potential firing through the long unmyelinated axons. Here, using human stem cell differentiated retinal ganglion cells (hRGCs) we have shown hRGCs are efficient in degrading damaged mitochondria and producing simultaneously healthy organelle for maintaining mitochondrial homeostasis.
However, a glaucomatous Optineurin mutant (E50K) hRGCs show high ATP production rate with fewer mitochondrion compared to the wild-type neurons causing mitochondrial swelling and disruption of homeostasis. Remarkably, enhancing mitochondrial biogenesis through pharmacological inhibition of the Tank binding kinase 1 (TBK1) restores energy homeostasis, mitigates mitochondrial swelling with neuroprotection against acute mitochondrial damage for glaucomatous hRGCs, revealing a novel neuroprotection mechanism.
Join Targeting Mitochondria 2023 to learn more about Prof. Arupratan Das's talk. Read more about Prof. Das's research.
Targeting Mitochondria 2023 Congress
October 11-13, 2023 - Berlin, Germany
Defining the Molecular Nature of the Mitochondrial permeability transition pore(s)
Prof. Paolo Bernardi from the University of Padova, Italy, will join the 14th edition of the World Conference on Targeting Mitochondria 2023 which will be held from October 11th to 13th in Berlin, Germany, and give a talk entitled "Defining the Molecular Nature of the Mitochondrial permeability transition pore(s)".
Major progress has been made in defining the basis of the mitochondrial permeability transition, a Ca2+-dependent permeability increase of the inner membrane that has puzzled mitochondrial research for almost 70 years. Initially considered an artifact of limited biological interest by most, over the years the permeability transition has raised to the status of regulator of mitochondrial ion homeostasis and of druggable effector mechanism of cell death. The permeability transition is mediated by the opening of channel(s) modulated by matrix cyclophilin D, the permeability transition pore(s) (PTP). The field has received a new impulse from the hypothesis that the PTP may originate from a Ca2+-dependent conformational change of F-ATP synthase and from the reevaluation of the long-standing hypothesis that it originates from the adenine nucleotide translocator. Prof. Bernardi will discuss potential mechanisms for PTP formation and the role of the permeability transition in pathophysiology.
Join Targeting Mitochondria 2023 to learn more about Prof. Bernardi's interesting talk.
Targeting Mitochondria 2023 Congress
October 11-13, 2023 - Berlin, Germany
Cardiac MitoMed: From Bench to Bedside
Dr. Sang-Bing Ong from The Chinese University of Hong Kong, China, will join the Targeting Mitochondria 2023 Congress and give a presentation entitled "Cardiac MitoMed: From Bench to Bedside".
Cardiovascular disorders remain the leading cause of death and disability worldwide. The extent of cardiac cell death and left ventricular systolic function are the strongest predictors of morbidity and mortality following cardiac disorders. Despite optimal therapy, the morbidity and mortality of cardiovascular patients remain significantly high. On this background, there remains an urgent clinical need to discover novel therapies for reducing cardiac injury/death and preserving cardiac function so as to improve health outcomes for cardiovascular patients.
In this regard, the viability of the heart and cardiac function is critically dependent on the ability of cardiac mitochondria to generate the energy required for optimal contractile function. Therefore, preventing mitochondrial dysfunction induced by cardiac disorders constitutes an important therapeutic strategy for preserving cardiac viability and function. As opposed to the conventional belief that the mitochondria are static organelles, mitochondria are actually dynamic whereby they change shapes (morphology) and shift locations in the cell. Studies from the last decade have focused on targeting the mitochondria so as to protect the heart. Nevertheless, results so far have been inconclusive.
Dr. Ong will present data from his team describing our efforts in modulating cardiac mitochondrial morphology to protect the heart against ischemia-reperfusion injury
Join Targeting Mitochondria 2023 to learn more about Dr. Ong's exciting talk.
Targeting Mitochondria 2023 Congress
October 11-13, 2023 - Berlin, Germany
Internalization of Exogenous Mitochondria for Endothelial Corneal Dystrophy Treatment
Dr. Patrick J. Rochette from Université Laval, Canada will join the Targeting Mitochondria 2023 Congress and give a presentation entitled "Internalization of Exogenous Mitochondria for Endothelial Corneal Dystrophy Treatment".
Fuchs' endothelial corneal dystrophy (FECD), a degenerative ocular disease, causes progressive vision loss that can lead to blindness. It is the leading cause of corneal transplantation, but the scarcity of grafts hinders its treatment. Dr. Rochette and his team have previously demonstrated a vicious cycle leading to FECD progression in which the mitochondria is central.
They have tested whether transplanting healthy mitochondria into FECD cells would improve pathological molecular markers of the disease. Using corneal endothelium explants from FECD patients, they demonstrated that incorporation of exogenous mitochondria into FECD cells by co-incubation reduces oxidative stress, increases mitochondrial membrane potential, and reduces mitophagy. In addition, internalization of exogenous mitochondria significantly reduces apoptosis.
Taken together, these results suggest that the internalization of exogenous mitochondria reverses the vicious circle involved in FECD, thus revealing a much-needed novel treatment alternative for FECD.
Join Targeting Mitochondria 2023 to learn more about Dr. Rochette's exciting talk. Read more about Dr. Rochette's research.
Targeting Mitochondria 2023 Congress
October 11-13, 2023 - Berlin, Germany
Stealth Therapeutics Will Exhibit during Targeting Mitochondria 2023
Stealth Therapeutics will showcase their latest innovations in mitochondrial medicine during Targeting Mitochondria 2023 in Berlin the October.
Dr. David A. Brown is Vice President of Mitochondrial Research at Stealth BioTherapeutics, and will give a short oral talk on “Translational insights from targeting mitochondria in rare diseases”.
Dr. Brown's talk will include an overview of Stealth’s clinical programs to date, including updates on targeting rare mitochondrial diseases in several Phase 2/3 clinical trials, as well as emerging approaches to mitigate mitochondrial dysfunction in pathologies.
About Stealth BioTherapeutics
Stealth BioTherapeutics is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Dysfunctional mitochondria are centrally involved in a number of rare genetic diseases and many common age-related diseases, typically involving organ systems with high energy demands such as the eye, the neuromuscular system, the heart and the brain.
World Mitochondria Society
14th Targeting Mitochondria 2023 Congress
October 11-13, 2023 - Berlin, Germany
LinkedIn | Facebook
